Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION:

 

THE USE OF "BIG DATA" - WHERE ARE WE AND WHAT DOES THE FUTURE HOLD?

 

The Use of "Big Data" in Health Care Decisions: Where are we and what does the future hold?

Marcus Wilson, PharmD

President, HealthCore, Wilmington, DE, USA

 

Using Big Data in Healthcare

David R. Holmes III, PhD

Collaborative Scientist, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN, USA

 

Statistical Methods and Machine Learning

William H. Crown, PhD

Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

 

Outcomes Research and Machine Learning: Complementary or Incompatible?

Lesley H. Curtis, PhD

Professor in Medicine, Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC, USA

 

SECOND PLENARY SESSION:

 

WHAT ARE THE ADVANTAGES AND DISADVANTAGES OF USING OBSERVATIONAL DATA AS THE BASIS OF DECISION MAKING IN HEALTH CARE? HOW COULD THIS AFFECT THE FUTURE OF RANDOMIZED CONTROLLED TRIALS?

 

Is It Time to Retire the Randomized Controlled Trial?

David Sackett, OC, FRSC, MD, MSc, FRCP

Professor Emeritus, Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada

 

Using Observational Data to Estimate Benefits and Harms of Health Care Interventions

David Henry, MB ChB, MRCP, FRCP

Senior Scientist, ICES Central and Professor, University of Toronto, Toronto, ON, Canada

 

THIRD PLENARY SESSION:

 

TO WHAT EXTENT SHOULD VALUE FOR MONEY DERIVED FROM HEALTH ECONOMIC ANALYSIS BE USED IN HEALTH CARE POLICY DECISION MAKING?

 

Why Do/Should We Do Economic Evaluation?

Tony Culyer, Hon DEcon, Hon FRCP, FRSA, FMedSci

Ontario Research Chair in Health Policy and System Design, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

 

PODIUM AND POSTER PRESENTATIONS
For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 19th Annual International Meeting, see: ISPOR Scientific Presentations Database an electronic database of over 27,000 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.
  • ISPOR Scientific Presentations Database: http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 19th Annual International Meeting – Montreal, Canada
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
WORKSHOP PRESENTATIONS

(Additional presentations will be added as speaker approval is received)

W1: CHANGING THE DRUG DEVELOPMENT PARADIGM

 

Exploring the Future of RE for Drugs in Europe

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, United Kingdom

 

Some Calls for Change

Penny Mohr, MA, Senior Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA

 

Scenario-building Methods and US Scenarios

Donna Messner, PhD, Research Director, Center for Medical Technology Policy, Baltimore, MD, USA

W4: MODELLING ALCHEMY: THE IMPACT OF UNORTHODOX TRIAL DESIGN ON HEALTH TECHNOLOGY APPRAISAL STRATEGY

 

Modelling Alchemy

Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York, NY, USA; Meghan Gallagher, Director, Global Health Economics and Outcomes Research, Oncology, Sanofi, Cambridge, MA, USA; Anthony Hatswell, MSc, Senior Health Economist, BresMed, Sheffield, United Kingdom; Marc Bardou, MD, PhD, Gastroenterologist, Centre Hospitalier Universitaire Le Bocage, Dijon, France

W8: MULTIVARIATE META-ANALYSIS: USE AND APPLICATIONS

 

Multivariate Meta-Analysis: Use and Applications

Sonya J Snedecor, PhD, Director, Health Economics, Pharmerit International, Bethesda, MD, USA; Yin Wan, MS, Associate Scientist, Pharmerit International, Bethesda, MD, USA; Joseph C. Cappelleri, PhD, MPH, MS, Senior Director, Biostatistics, Pfizer Inc, Groton, CT, USA; John William Stevens, PhD, Statistician, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, United Kingdom

W11: HOW CAN WE USE RANDOMIZED TRIAL DATA TO ASSESS HETEROGENEITY OF TREATMENT EFFECTS? LET ME COUNT THE WAYS

 

How Can We Use RCT Data to Assess Heterogeneity of Treatment Effects? Let Me Count the Ways

Robert W. Dubois, MD, PhD, Chief Scientist, National Pharmaceutical Council, Washington, DC, USA

 

HTE: Biologic and Non-Biologic Factors

C Daniel Mullins, PhD, Professor, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

 

Individual Patient Data And Meta-Analytic Techniques: Some Alternative Methods

Richard Willke, PhD, Group Lead, Outcomes & Evidence, Pfizer Inc., Peapack, NJ, USA

W12: A FRAMEWORK FOR CONDUCTING INITIAL MEDICATION ADHERENCE RESEARCH

 

A Framework For Conducting Initial Medication Adherence Research

David Hutchins, MBA, Executive Advisor, Caremark, Scottsdale, AZ, USA; Andrew M. Peterson, PharmD, PhD, Dean, Mayes College of Healthcare Business and Policy, University of the Sciences, Philadelphia, PA, USA; Craig S Roberts, PharmD, MBA, Senior Director, Outcomes Research, Pfizer Inc., New York, NY, USA; John E Zeber, PhD, MHA, Investigator & Associate Professor, Center for Applied Health Research, Scott & White Healthcare, Temple, TX, USA

W13: EVIDENCE SYNTHESIS AND DECISION MAKING WHEN RANDOMISED EVIDENCE DOES NOT SUFFICE

 

Evidence Synthesis and Decision Making: Is There a Role for Non-Randomized Evidence?

Doug Coyle, PhD, Professor, Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada

W17: UNDERSTANDING AND MODELING BUSINESS DECISIONS IN MARKET ACCESS AND REIMBURSEMENT USING MULTI-CRITERIA DECISION ANALYSIS TECHNIQUES

 

MCDM and MCDA: A Company Perspective

Ansgar Hebborn, PhD, Head, Global Market Access Policy, F. Hoffmann-La Roche AG, Basel, Switzerland

 

Understanding and Modeling Business Decisions in Market Access and Reimbursement Using Multi-Criteria Decision Analysis Techniques

Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, Netherlands; Kevin Marsh, PhD, Senior Research Scientist & EU Director, Modelling and Simulation, Evidera, London, United Kingdom; Tereza Lanitis, MSc, Research Associate, Health Economic Modelling and Simulation, Evidera, London, United Kingdom

 

Methodological issues related to the use of MCDA for modeling business decisions

Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, Netherlands

W20: EXPLORING AND VALIDATING ALTERNATIVE METHODS OF USING MULTIPLE DATABASES TO ANSWER COMPLEX LONGITUDINAL RESEARCH QUESTIONS: IS LINKING DATABASES THE ONLY ANSWER?

 

Exploring and Validating Alternative Methods of Using Multiple Databases to Answer Complex Longitudinal Research Questions: Is Linking Databases the Only Answer?

Rolin L Wade, RPh, MS, Principal, Health Economics and Outcomes Research, Real World Evidence Solutions, IMS Health, Parsippany, NJ, USA; David Macarios, MBA, Vice President, Health Economics and Outcomes Research, LifeCell Corporation, Bridgewater, NJ, USA

W25: GOOD PRACTICE GUIDELINES FOR QALYs: ISPOR'S DANGEROUS OMISSION?

 

Good Practice Guidelines for QALYs – ISPOR's Dangerous Omission?

Christopher McCabe, MSc, PhD, Professor, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; John Brazier, PhD, Professor, Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, United Kingdom; David M Meads, MSc, Lecturer, Academic Unit of Health Economics, University of Leeds, Leeds, United Kingdom

W27: EXPECTED VALUE OF PERFECT INFORMATION: ACTIVE LEARNING THROUGH USER-FRIENDLY COMPUTATIONS, DISPLAYS, AND APPLICATION DISCUSSIONS

 

Expected Value of Perfect Information: Active Learning Through User-Friendly Computations, Displays, and Application Discussions

R. Brett McQueen, PhD, Post Doctoral Fellow, School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Eldon Spackman, PhD, Research Fellow, Centre for Health Economics, The University of York, Heslington, York, United Kingdom; Jonathan D Campbell, PhD, Assistant Professor, School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

W30: QUANTITATIVE CHALLENGES FACING PATIENT-CENTERED OUTCOMES RESEARCH

 

Dimensionality and Differential Item Functioning

Wen-Hung Chen, PhD, Director of Psychometrics, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA

 

Maximizing Response Rates by Minimizing Burden

Maria Orlando Edelen, PhD, Senior Behavioral Scientist, RAND Corporation, Boston, MA, USA

W31: EVALUATION OF THE BARRIERS AND OPPORTUNITIES OF BIG DATA IN HEALTH OUTCOMES RESEARCH

 

Evaluation of the Barriers and Opportunities of Big Data in Health Outcomes Research

Diana Brixner, PhD, RPh, Professor & Chair, Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA; Maggie Gunter, PhD, Director of Medical Outcomes Research, Lovelace Respiratory Research Institute, Albuquerque, NM, USA; Manuel Prado, BA, President & CEO, Real Health Data, Santa Cruz, CA, USA

ISSUE PANELS

(Additional presentations will be added as speaker approval is received)

IP1: CROSS-FUNCTIONAL COLLABORATION ON CER - WHY CAN'T WE WORK TOGETHER?

 

Does Health Economics Have A Role In The New Era Of Personalized Medicine?

Sebastian Schneeweiss, MD, ScD, Professor of Medicine and Epidemiology, Harvard Medical School, Boston, MA, USA; Robert Epstein, MD, MS, CEO & President, Epstein Health, LLC., Woodcliff Lake, NJ, USA; Lesley H. Curtis, PhD, Professor in Medicine, Duke University School of Medicine, and Duke Clinical Research Institute, Durham, NC, USA

IP2: DOES HEALTH ECONOMICS HAVE A ROLE IN THE NEW ERA OF PERSONALIZED MEDICINE?

 

Does Health Economics Have A Role In The New Era Of Personalized Medicine?

Scott Ramsey, MD, PhD, Member, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Anirban Basu, MS, PhD, Professor, Health Services, University of Washington, Seattle, WA, USA; John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA; David L. Veenstra, PharmD, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

IP3: WHAT IS THE BEST WAY TO USE MCDA IN HEALTH TECHNOLOGY APPRAISAL?

 

What is The Best Way to Use Mcda in Health Technology Appraisal?

Nancy Devlin, PhD, Research Director, Office of Health Economics, London, United Kingdom

 

Where Might MCDA Fit into Analyses to Support Decision Making?

Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, United Kingdom

 

Structuring Complex Evidence and Values: A Role for Multi-Criteria Decision Analysis (MCDA) in HTA?

Stuart Peacock, DPhil, Co-Director, Cancer Control Research, BC Cancer Agency, Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada

 

What is the Best Way to Use MCDA in HTA?

Josie Godfrey, BA, MAs, Associate Director, Highly Specialised Technologies, National Institute for Health and Clinical Excellence (NICE), London, United Kingdom

IP4: IS IT TIME FOR A NEW DRUG DEVELOPMENT PARADIGM?

 

Is it Time for a New Drug Development Paradigm?

Penny Mohr, MA, Senior Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA

 

Is it Time for a New Drug Development Paradigm?

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, United Kingdom

 

Is it Time for a New Drug Development Paradigm?

Robert McDonough, MD, JD, MPP, Head, Clinical Policy Research and Development, Aetna, Hartford, CT, USA

IP5: REAL-WORLD EVIDENCE: IS IT FIT FOR PURPOSE? AND IF SO, WHEN?

 

Real-World Evidence: Is it Fit for Purpose? And if So, When?

Jennifer S. Graff, PharmD, Director, Comparative Effectiveness Research, National Pharmaceutical Council, Washington, DC, USA; Raj Sabharwal, MPH, Senior Manager, AcademyHealth, Washington DC, USA; Steven Pearson, MD, MSc, FRCP, President, Institute for Clinical and Economic Review, Boston, MA, USA; Reed Tuckson, MD, FACP, Managing Director, Tuckson Health Connections, Edina, MN, USA

IP6: VALUING TARGETED THERAPIES AND THEIR COMPANION TESTS – ARE WE LEAVING SOME OF THE VALUE ON THE BENCH (OR AT THE BEDSIDE)?

 

Valuing Targeted Therapies and Their Companion Tests – Are We Leaving Some of the Value On The Bench (or at the Bedside)?

Scott Ramsey, PhD, MD, Member and Professor, Public Health Sciences, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA; Adele R. Weston, PhD, Executive Vice President & Senior Scientist, Health Economics and Outcomes Research, Optum, Sydney, Australia; Deborah Marshall, PhD, Associate Professor, Community Health Sciences, University of Calgary, Calgary, AB, Canada

IP8: GUIDELINES AND STANDARDS FOR OBSERVATIONAL STUDIES: ARE WE HEADED FOR DISCOURSE OR HARMONY?

 

Guidelines And Standards For Observational Studies: Are We Headed For Discourse Or Harmony?

Robert W. Dubois, MD, PhD, Chief Scientist, National Pharmaceutical Council, Washington, DC, USA; Rachael Fleurence, PhD, Program Director, Comparative Effectiveness Research (CER) Methods and Infrastructure Program, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Sally C. Morton, PhD, Professor & Chair, Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

IP9: THE NEXT FRONTIER FOR RISK-SHARING AGREEMENTS IN THE UNITED STATES: DOES THE CHANGING HEALTH CARE LANDSCAPE BRING NEW PROMISE FOR PARTNERSHIPS BETWEEN MANUFACTURERS AND PAYERS?

 

The Next Frontier For Risk-sharing Agreements In The United States: Does The Changing Health Care Landscape Bring New Promise For Partnerships Between Manufacturers And Payers?

Josh J. Carlson, MPH, PhD, Assistant Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA; Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, United Kingdom; Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

IP9: THE NEXT FRONTIER FOR RISK-SHARING AGREEMENTS IN THE UNITED STATES: DOES THE CHANGING HEALTH CARE LANDSCAPE BRING NEW PROMISE FOR PARTNERSHIPS BETWEEN MANUFACTURERS AND PAYERS?

 

The Next Frontier For Risk-sharing Agreements In The United States: Does The Changing Health Care Landscape Bring New Promise For Partnerships Between Manufacturers And Payers?

Josh J. Carlson, MPH, PhD, Assistant Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA; Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, United Kingdom; Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

IP10: ARE WE GETTING REAL ABOUT REAL-WORLD EVIDENCE REQUIREMENTS?

 

Are We Getting Real About Real-world Evidence Requirements?

Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA; John P. Graham, PharmD, Executive Director, Health Services, Health Economics and Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ, USA; Richard Lieblich, RPh, Vice President, Industry Relations, MedImpact Healthcare Systems, Inc., San Diego, CA, USA; John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA

IP12: IS THE US MEDICARE PROGRAM'S USE OF COMPARATIVE EFFECTIVENESS RESEARCH CONSISTENT WITH THE AFFORDABLE CARE ACT'S RESTRICTIONS?

 

Is the US Medicare Program's Use of Comparative Effectiveness Research Consistent with the Affordable Care Act's Restrictions?

Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Penny Mohr, MA, Senior Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA; Art Small, MD, Head, Oncology Outcomes Research, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA; James D. Chambers, PhD, MPharm, MSc, Assistant Professor, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

IP13: IS HTA MORE SIMILAR THAN DIFFERENT ACROSS THE ATLANTIC? COMPARISON OF CANADA AND EUROPE

 

Is HTA More Similar than Different across the Atlantic? Comparison of Canada and Europe

Lou Garrison, PhD, Professor & Associate Director, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

 

Is HTA More Similar than Different across the Atlantic? An European perspective

Wim Goettsch, PhD, Project Leader, EUnetHTA WP5 on Relative Effectiveness of Pharmaceuticals and Advisor of International Affairs and Academia, Health Care Insurance Board (CVZ), Diemen, Netherlands

 

Is HTA More Similar than Different across the Atlantic? Comparison of Canada and Europe

Adrian D. Griffin, MSc, Vice President, HTA & Market Access Policy, Johnson & Johnson, Buckinghamshire, United Kingdom

 

Is HTA More Similar than Different across the Atlantic? Perspectives From Canada

Tammy Clifford, PhD, Vice President, Strategic Initiatives & Chief Scientist, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

IP14: VALUE-BASED PRICING ACROSS INDICATIONS: ARE THE CONCEPTUAL AND IMPLEMENTATIONAL CHALLENGES WORTH IT?

 

Value Based Pricing across Indications: Are the Conceptual and Implementational Challenges Worth it?

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, United Kingdom

 

Value-Based Pricing across Indications: A Company Perspective

Ansgar Hebborn, PhD, Head, Global Market Access Policy, F. Hoffmann-La Roche AG, Basel, Switzerland

 

Value-Based Pricing across Indications: Are the Conceptual nd Implementational Challenges Worth it?

Paolo Daniele Siviero, MS, Head of Economic Strategy & Pharmaceutical Policy, Director of Pharmaceutical Policy Unit, Italian Medicines Agency (AIFA), Rome, Italy

IP18: RISK SHARING FOR MEDICAL DEVICES: HAS THE TIME COME?

 

Risk Sharing for Medical Devices: Has the time come?

Susan Garfield, DrPH, Vice President, Market Access, Health, GfK Bridgehead, Wayland, MA, USA

 
ISPOR FORUMS

(Presentations will be added as speaker approval is received)

ISPOR CLINICIAN REPORTED OUTCOMES GOOD MEASUREMENT PRACTICES

Presented by the ISPOR Clinician Reported Outcomes Good Measurement Practices Task Force

ISPOR Clinician Reported Outcomes Good Measurement Practices

John H. Powers, III, MD, FACP, FIDSA, Senior Medical Scientist, SAIC in Support to Collaborative Clinical Research Branch (CCRB), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and Associate Clinical Professor of Medicine, George Washington University School of Medicine, Washington, DC, USA; Laurie B. Burke, RPh, MPH, Former Associate Director for Study Endpoints and Labeling Office of New Drugs, CDER, U.S. Food & Drug Administration (FDA) and Founder, LORA Group, LLC, Royal Oak, MD, USA; Patrick Marquis, MD, MBA, President, Twolegs Consulting, Newton, MA, USA; Ashley Slagle, PhD, MS, Endpoints Reviewer, SEALD, ONDIO, CDER, U.S. Food & Drug Administration (FDA), Silver Spring, MD, USA

SIMULATION MODELING APPLICATIONS IN HEALTH CARE DELIVERY RESEARCH — EMERGING GOOD PRACTICES
Presented by the ISPOR Simulation Modeling Applications in Health Care Delivery Research - Emerging Good Practices Task Force

Simulation Modeling Applications In Health Care Delivery Research
Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada; William Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA; Maarten J. IJzerman, PhD, Professor of Clinical Epidemiology & Health Technology Assessment (HTA) and Head, Department of Health Technology & Services Research, University of Twente, MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, Netherlands

RARE DISEASES: CHALLENGES IN ASSESSMENT AND APPRAISAL OF DIAGNOSTICS & TREATMENTS

Presented by the ISPOR Rare Disease SIG:  Challenges in Assessment and Appraisal of Diagnostics & Treatments Working Group Presented by the ISPOR Rare Disease SIG: Challenges in Assessment and Appraisal of Diagnostics & Treatments Working Group

Rare Disease Challenges in Assessment and Appraisal of Diagnostics & Treatments Working Group

Chris L. Pashos, PhD, Vice President, Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA; Mondher Toumi, MD, MSc, PhD, Professor & Chair of Decision Sciences, Department of Public Health and Market Access, University Claude Bernard Lyon I, Lyon, France; Christopher Blanchette, PhD, MBA, Associate Dean for Research, College of Health and Human Services, University of North Carolina at Charlotte, Charlotte, NC, USA; Daria Korchagina, MBE, Pricing & Market Access Analyst, Creativ-Ceutical, Paris, France

WHAT IS VALUE IN HEALTH DOING FOR ITS AUTHORS?

Presented by the Co-Editors-in-Chief of Value in Health

What Is Value In Health Doing For Its Authors?

Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, United Kingdom; C. Daniel Mullins, PhD, Co-Editor-in-Chief, Value in Health and Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

CONJOINT ANALYSIS - STATISTICAL ANALYSES, RESULTS & CONCLUSIONS GOOD RESEARCH PRACTICES

Presented by the ISPOR Conjoint Analysis - Statistical Analyses, Results & Conclusions Good Research Practices Task Force

Conjoint Analysis: Statistical Analysis

A. Brett Hauber, PhD, Senior Economist and Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada; Juan Marcos González, PhD, Senior Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

HOW VARIATION IN HTA PROCESSES AND REQUIREMENTS FOR MOLECULAR DIAGNOSTICS CREATES CHALLENGES FOR MANUFACTURER, PAYER, AND CLINICAL STAKEHOLDERS

Presented by the ISPOR Medical Devices and Diagnostics Special Interest Group

How Variation in HTA Processes and Requirements for Molecular Diagnostics Creates Challenges for Manufacturer, Payer, and Clinical Stakeholders

Susan Garfield, DrPH, Vice President, Market Access, Health, GfK Bridgehead, Wayland, MA, USA; Michael Longacre, BS, North American Market Access, Global Health Economics and Reimbursement, Beckman Coulter, Inc., Yamhill, OR, USA; Julie Polisena, MSc, Scientific Advisor, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada; Eric Faulkner, MPH, Director, Global Market Access, Quintiles, Durham, NC, USA

PRO AND OBSRO MEASUREMENT IN RARE DISEASE CLINICAL TRIALS – EMERGING GOOD PRACTICES

Presented by the ISPOR PRO and ObsRO Measurement in Rare Disease Clinical Trials Emerging Good Practices Task Force

Pro And Obsro Measurement In Rare Disease Clinical Trials – Emerging Good Practices

Margaret Vernon, PhD, Senior Research Scientist, Outcomes Research, Evidera, London, United Kingdom; Katy Benjamin, PhD, Director, Patient Reported Outcomes, ICON Commercialisation and Outcomes, Bethesda, MD, USA; Laurie B. Burke, RPh, MPH, Former Associate Director for Study Endpoints and Labeling Office of New Drugs, CDER, U.S. Food & Drug Administration (FDA) and Founder, LORA Group, LLC, Royal Oak, MD, USA; Eleanor Perfetto, PhD, MS, Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

RARE DISEASE TERMINOLOGY & DEFINITIONS USED IN OUTCOMES RESEARCH

Presented by the Rare Disease SIG: Terminology & Definitions Used in Outcomes Research Working Group

Rare Disease: Terms & Definitions Used in Outcomes Research

Zeba Khan, PhD, RPh, Vice President, Strategic Market Access & Policy, Celgene, Summit, NJ, USA; Trevor Richter, PhD, MSc, Research Manager, Health Economics, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada; Robert Babela, PhD, MSc, Head of Department of Public Health, HM, St. Elizabeth University, Bratislava, Slovak Republic

CAPACITY BUILDING IN PHARMACOECONOMICS IN THE ARABIC-SPEAKING COUNTRIES: CHALLENGES & OPPORTUNITIES IN EDUCATION AND TRAINING

Presented by the ISPOR Arabic Network

Capacity Building In Pharmacoeconomics In The Arabic-speaking Countries: Challenges & Opportunities In Education And Training

Ola Ghaleb Al Ahdab, PhD, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates; Daoud Al-Badriyeh, BPharm, PhD, President, ISPOR Qatar Chapter and Assistant Professor of Pharmacoeconomics, College of Pharmacy, Qatar University, Doha, Qatar;

Abdulaziz H. Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia; Ibrahim Al-Abbadi, PhD, MBA, BPharm, President, ISPOR Jordan Chapter and Dean, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan; Gihan Hamdy Elsisi, RPh, MSc, Head of Pharmacoeconomic Unit and Part-time Lecturer of Pharmacoeconomics, Central Administration for Pharmaceutical Affairs, Ministry of Health, Faculty of Pharmacy Helwan University, Cairo, Egypt

HEALTH CARE IN AFRICA: CAN BIG DATA IMPROVE OUTCOMES?

Presented by the ISPOR Africa Network

Health Care in Africa: Can Big Data Improve Outcomes?

Anthony Waka Udezi, PhD, Assistant Dean of Pharmacy and Senior Lecturer, Department of Clinical Pharmacy, University of Benin, Benin City, Nigeria; Gihan Hamdy Elsisi, RPh, MSc, Head of Pharmacoeconomic Unit and Part-time Lecturer of Pharmacoeconomics, Central Administration for Pharmaceutical Affairs, Ministry of Health, Faculty of Pharmacy Helwan University, Cairo, Egypt;

Ernest Attuquaye Quaye, BPharm, MPH, Principal Pharmacist, Medical Department, Ghana Cocoa Board, Accra, Ghana

 
EDUCATIONAL SYMPOSIA

(Presentations will be added as symposia host approval is received)

 

YOU GET WHAT YOU PAY FOR: WILL ACOS UNDERUSE DRUGS?
Sponsored by National Pharmaceutical Council

You Get What You Pay For: Will Accountable Care Underuse Drugs?
Kimberly D. Westrich, MA, Director, Health Services Research, National Pharmaceutical Council, Washington, DC, USA

 

Accountable Care Measures for Specialty Care and Innovative Treatment
Tom Valuck, MD, JD, Partner, Discern Health, Baltimore, MD, USA

 

Quality Measurement and ACOs - Thoughts from a Researcher's Perspective
Robert Epstein, MD, MS, President & CEO, Epstein Health, LLC, Woodcliff Lake, NJ, USA

 

You Get What You Pay For?: a Health Plan Perspective
Andrew Baskin, MD, National Medical Director for Quality and Provider Performance Measurement, Aetna, Blue Bell, PA, USA

PREDICTIVE ANALYTICS: PROVIDING NOVEL APPROACHES TO ENHANCE OUTCOMES RESEARCH LEVERAGING BIG AND COMPLEX DATA
Sponsored by IMS Health

Predictive Analytics: Providing Novel Approaches To Enhance Outcomes Research Leveraging Big And Complex Data
Michael Nelson, PharmD, Senior Principal & Regional Leader, Americas, Real-World Evidence Solutions & HEOR, IMS Health, Alexandria, VA, USA; Jonathan C. Silverstein, MD, MS, FACS, FACMI, Vice President & Davis Family Chair of Informatics, Head, Center for Biomedical Research Informatics (CBRI) NorthShore University HealthSystem, and Research Associate (Professor of Surgery), University of Chicago Pritzker School of Medicine, Evanston, IL, USA; John Rigg, PhD, Senior Manager, Advanced Analytics, Real-World Evidence Solutions, IMS Health, London, United Kingdom

EMERGING ACCESS BARRIERS AND EVIDENCE REQUIREMENTS FOR ONCOLOGY THERAPIES: EXPERIENCES ACROSS THREE COUNTRIES
Sponsored by Xcenda

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.